SCM
CRVS icon

Sterling Capital Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Sterling Capital Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.12K Buy
418
+26
+7% +$415 ﹤0.01% 2636
2025
Q4 		$3.02K Buy
392
+248
+172% +$1.96K ﹤0.01% 3005
2025
Q3 		$1.06K Buy
144
+17
+13% +$87 ﹤0.01% 3074
2025
Q2 		$508 Buy
+127
New +$462 ﹤0.01% 3151

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sterling Capital Management's CRVS Position: Q1 2026 in Review

Sterling Capital Management increased its Corvus Pharmaceuticals (CRVS) stake by 6.6% in Q1 2026, buying an estimated $415 and bringing the position to 418 shares worth $6.12K. The position accounts for ﹤0.01% of the portfolio, ranked #2636.

Sterling Capital Management first reported a position in CRVS in Q2 2025 and has held it in 4 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Sterling Capital Management held 418 shares of Corvus Pharmaceuticals worth $6.12K as of Q1 2026.
  • Sterling Capital Management bought 26 Corvus Pharmaceuticals shares in Q1 2026, an estimated $415.
  • Corvus Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #2636 holding.
  • Sterling Capital Management first reported a position in Corvus Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.